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CORRESPONDENCE
Letters to the Editor
Angiotensin-Converting Enzyme Inhibitors
and Outcome Among Patients With
Heart Failure and Renal Insufficiency:
Need for a Prospective Study
Ezekowitz et al. (1) recently reported lack of benefit of
angiotensin-converting enzyme (ACE) inhibitors on mortality in
patients with chronic heart failure (CHF) in whom estimated
creatinine clearance was below 60 ml/min, as opposed to a
beneficial effect in those with creatinine clearance above 60
ml/min. The researchers attribute this lack of benefit to a possible
interaction between aspirin and ACE inhibitor use, suggesting that
aspirin might blunt the effects of ACE inhibitors. Whereas this
might be true, in our opinion another explanation should be
considered as well, namely prescription bias. In CHF, ACE
inhibition should be prescribed to all patients, especially in those
with severe CHF. Regretfully, this is not always true in daily
practice.
In the cohort studied by Ezekowitz et al. (1), only 60% were
using ACE inhibitors. It has been reported that physicians are
reluctant to prescribe ACE inhibitors in the presence of severe
renal dysfunction (2). Physicians are more willing to prescribe
ACE inhibitors to CHF patients if such patients are more
symptomatic (3). In CHF, renal function impairment can elicit a
clinically more unstable condition—for instance, by fluid retention.
Accordingly, in the present study by Ezekowitz et al. (1), con-
founding by prescription may have occurred among the patients
with renal function impairment, with ACE inhibitors being
preferentially prescribed to subjects with a more unstable cardiac
condition and a worse prognosis.
In view of the prognostic importance of renal function in
subjects with CHF, it might be relevant that, in subjects with
primary renal disease and severely impaired renal function, ACE
inhibition protects against further worsening of renal function (4).
Whether this might be of benefit in CHF patients has not been
studied so far. Taken together, the data by Ezekowitz et al. (1)
argue for prospective studies into the role of ACE inhibitors in
CHF subjects with renal function impairment.
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Beta-Blockers Versus Digoxin to Control
Ventricular Rate During Atrial Fibrillation
The recent study of Olshansky et al. (1) investigated the approaches
used to control rate, the effectiveness of rate control, and changeovers
from one drug class to another in the Atrial Fibrillation Follow-up
Investigation of RhythmManagement (AFFIRM) study. Comparing
the cumulative achievement of adequate ventricular rate control and
the time to discontinuation of rate-control therapy, the investigators
concluded that beta-blockers were the most effective drugs. We
believe the superiority of beta-blockers over other therapeutic options,
particularly over digoxin, must be interpreted with caution.
Adequate ventricular rate control was cumulatively obtained in
a similar proportion of patients taking beta-blockers alone and
digoxin alone (59% vs. 58%, respectively), a result that was
confirmed both during rest (68% for both therapies) and with
exertion (72% vs. 70%, respectively). Afterwards, the researchers
considered beta-blockers more effective, observing that, over time,
more patients taking digoxin or a calcium channel blocker were
changed to another drug (p  0.0001). However, in this compar-
ison, the group of patients using beta-blockers and calcium
channel antagonists included those taking digoxin concomitantly,
whereas the digoxin group included only individuals using this
drug alone. It is possible to observe that, in patients using
beta-blockers, the association of digoxin increased the proportion
of adequate rate control from 59% to 70%, and this increment may
have led to the observed superiority with beta-blocker therapy.
Randomized studies have already demonstrated that the associa-
tion of digoxin with beta-blockers is more effective than beta-
blockers alone in this setting (2,3).
In their discussion, the investigators (1) stated that “because no
placebo control was used in this trial, it is possible that no
medication would have worked as well as digoxin did to control the
rate.” Because the randomization of the AFFIRM trial was not
performed to compare drugs to control ventricular rate, this
observation should not be restricted to digoxin. The concept that
oral digoxin is efficient in controlling ventricular rate during atrial
fibrillation is well accepted (4), despite being supported more by
studies that demonstrated the reduction of ventricular rate after the
initiation of the therapy (5) than by the sparse number of
randomized placebo-controlled trials (6).
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In conclusion, we do believe that the report by Olshansky et al.
(1) from the AFFIRM study does not allow the conclusion that
“beta-blockers were the most effective drugs” in controlling ven-
tricular rate during atrial fibrillation. In their study, the efficacy of
beta-blockers and digoxin, both used alone, was equivalent. Our
opinion, in accordance with current guidelines for the management
of atrial fibrillation, is that digoxin is still a first-line alternative to
control ventricular rate in patients with atrial fibrillation, particu-
larly in cases with congestive heart failure and left ventricular
systolic dysfunction (4).
*Henrique H. Veloso, MD
Angelo A. V. de Paola, MD
*VOTCOR
Hospital da Venerável Ordem Terceira da Penitência
Rua Conde de Bonfim 1033
Rio de Janeiro
Brazil
E-mail: hhorta@cardiol.br
doi:10.1016/j.jacc.2005.03.015
REFERENCES
1. Olshansky B, Rosenfeld LE, Warner AL, et al., and the AFFIRM
Investigators. The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study: approaches to control rate in
atrial fibrillation. J Am Coll Cardiol 2004;43:1201–8.
2. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular
rate control in chronic atrial fibrillation during daily activity and
programmed exercise: a crossover open-label study of five drug regi-
mens. J Am Coll Cardiol 1999;33:304–10.
3. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG.
Carvedilol alone or in combination with digoxin for the management of
atrial fibrillation in patients with heart failure? J Am Coll Cardiol
2003;42:1944–51.
4. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines and Policy
Conferences (Committee to Develop Guidelines for the Management
of Patients with Atrial Fibrillation): developed in collaboration with the
North American Society of Pacing and Electrophysiology. J Am Coll
Cardiol 2001;38:1231–66.
5. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone
and in combination with low-dose diltiazem or betaxolol to control
ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88–
90.
6. Ang EL, Chan WL, Cleland JG, et al. Placebo controlled trial of
xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J
1990;64:256–60.
REPLY
We appreciate the interest of Drs. Veloso and de Paola and their
comments about our study (1).
We did not specifically recommend beta-blockers as the first-
line approach to rate control of atrial fibrillation in all patients.
Other therapeutic options, such as digoxin, may indeed be a more
appropriate first step in individual circumstances.
In the Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) trial, more patients were switched to
beta-blockers than to other drug classes. Often, combination
therapy was needed. The question “is there one best approach?
cannot be answered definitively from our data for several reasons:
1. Rate control can be difficult. Drugs had to be changed in about
one-third of patients in the AFFIRM study. Effective rate
control may require open-mindedness to all rate-control op-
tions; there may be no one best approach for all patients.
2. Our study did not randomize the rate-control strategies. Some
patients required a beta-blocker or digoxin for other clinical
reasons. Beta-blockers may be necessary if the patient has
certain conditions, such as coronary artery disease, whereas
digoxin may be a first-line alternative when congestive heart
failure and left ventricular systolic dysfunction are present.
3. Rate control is difficult to define. The need for a specific rate
may vary by patient, by disease, and by drug. It is possible that
AFFIRM’s approach to rate control was too stringent or was
not targeting the correct rate.
4. Rate control might not be the only important end point in
managing atrial fibrillation with rate-controlling drugs. These
drugs may increase or decrease symptoms despite proper rate
control, influence mortality, affect total costs, influence hospi-
talization rates, or influence the return to sinus rhythm. These
factors, not explored in our report, must be considered for any
patient requiring therapy for rate control, and drug classes may
differ in this regard.
5. We could not analyze the combination of beta-blockers and
digoxin because start and stop dates for drug use were not
recorded in the AFFIRM study. Although it was possible to
determine whether neither drug was used, it was not possible
to determine whether both drugs were used concurrently.
The success of achieving rate control in the AFFIRM study may
have hinged on the flexibility of the investigators to use more than
one drug class. Over the long run, more patients were switched to
beta-blockers than to the other drug classes. Beta-blockers tended
to be used more commonly over time, and fewer patients aban-
doned this drug class. Of importance, rate control was possible for
the majority of patients without the need for atrioventricular
junctional ablation and a pacemaker, and rate control appeared to
improve over time.
We do not necessarily advocate a beta-blocker as first-line
therapy for rate control for all patients. Digoxin may be reasonable
as first-line therapy in some patients, especially sedentary elderly
patients.
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